Third Time's The Charm? Oritavancin Finds New Home With Targanta
This article was originally published in The Pink Sheet Daily
Executive Summary
Indianapolis-based private biotech firm will take over development of the Lilly-developed Phase III antibiotic, which was previously held by InterMune.
You may also be interested in...
Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market
Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.
Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market
Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.
InterMune Phase III Efforts Will Be Funded Through Infergen Sale
Proceeds from InterMune’s sale of the hepatitis C agent to Valeant will be used for development of idiopathic pulmonary fibrosis therapies.